← Leaderboards
Markos Leggas
University Of Kentucky
$4,898,273
Attributed
$8,667,808
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,667,808 · 6
By mechanism
R01$6,541,536 · 2
P20$1,409,136 · 2
R21$410,200 · 1
P30$306,936 · 1
Top collaborators
- Henrietta S. Bada6 shared
- Jurgen Tiberius Rohr5 shared
- Oleg V Tsodikov5 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Russell J Mumper$6,017,636
- Jin-Ming Yang$5,088,324
- Ching-Shih Chen$8,095,534
- William H St Clair$3,066,919
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsPharmaceutical PreparationsToxic EffectPropertyCellsIn VitroDesignChildPharmacologyCollaborationsAffectNatural ProductsTranscription FactorMetabolismReportingReporterScreeningPreventPublic HealthCytotoxicityComplementProgramsBiologicalPilot Projects
Grant awards (19)
Center for Translational Pharmacology$306,936
P30 · FY2025 · CA · contact PI
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma$551,064
R01 · FY2024 · CA
Translational Core$221,077
P20 · FY2024 · GM · contact PI
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma$579,770
R01 · FY2023 · CA
Translational Core$250,113
P20 · FY2023 · GM · contact PI
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma$592,330
R01 · FY2022 · CA
Translational Core$279,204
P20 · FY2022 · GM · contact PI
Non-opiate treatment after prenatal opiate exposure to Prevent Postnatal Injury to the Young Brain (No-POPPY)$715,386
R01 · FY2021 · DA
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma$617,234
R01 · FY2021 · CA
Translational Core$257,010
P20 · FY2021 · GM · contact PI
Non-opiate treatment after prenatal opiate exposure to Prevent Postnatal Injury to the Young Brain (No-POPPY)$729,160
R01 · FY2020 · DA
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma$652,202
R01 · FY2020 · CA · contact PI
Translational Core$401,732
P20 · FY2020 · GM · contact PI
Non-opiate treatment after prenatal opiate exposure to Prevent Postnatal Injury to the Young Brain (No-POPPY)$735,814
R01 · FY2019 · DA
Non-opiate treatment after prenatal opiate exposure to Prevent Postnatal Injury to the Young Brain (No-POPPY)$603,677
R01 · FY2018 · DA
Non-opiate treatment after prenatal opiate exposure to Prevent Postnatal Injury to the Young Brain (No-POPPY)$152,783
R01 · FY2018 · DA
Non-opiate treatment after prenatal opiate exposure to Prevent Postnatal Injury to the Young Brain (No-POPPY)$612,116
R01 · FY2017 · DA
Phase I and Biological Studies of DB67 - A Blood Stable Camptothecin$205,100
R21 · FY2008 · CA · contact PI
Phase I and Biological Studies of DB67 - A Blood Stable Camptothecin$205,100
R21 · FY2007 · CA · contact PI